NCT01847391

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy subjects.

Conditions

• Ischemic Heart Disease

Interventions

Type	Name	Description
DRUG	GS-6615	GS-6615 tablet(s) administered orally once daily
DRUG	Placebo	Placebo tablet(s) to match GS-6615 administered orally once daily

Timeline

• Start date: 2013-05-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2013-05-06
• Last updated: 2013-11-13

Locations

1 site across 1 country: United States